Plasma levels of adrenomedullin, a vasoactive peptide, in type 2 diabetic patients with and without retinopathy.
ABSTRACT The aim of this study was to investigate whether adrenomedullin (AM) secretion is modified in type 2 diabetic patients with and without retinopathy.
The study was performed on 92 patients with type 2 diabetes, 65 of whom had uncomplicated diabetes, 27 had retinopathy, and 40 had mild to moderate hypertension. Patients with serum creatinine levels >1.2 mg/dL, were excluded. Circulating AM was assayed using a specific radioimmunoassay.
AM concentrations were significantly higher in type 2 diabetic patients (25+/-2.1 pg/mL) than in the 31 normal subjects (11+/-0.8 pg/mL) (P<0.001). Type 2 diabetic patients with retinopathy had significantly greater AM levels (30.8+/-3.4 pg/mL) than both controls (P<0.001) and type 2 diabetic patients without retinopathy (25.2+/-2 pg/mL same as previous value) (P<0.001). No statistical difference was found between diabetic patients with pre-proliferative retinopathy (27.3+/-4.7 pg/mL) and proliferative retinopathy (24+/-3.1 pg/mL) (P=0.543). In type 2 diabetic patients, a significant correlation between plasma AM levels and HbA1c values (r=0.467; P<0.01) was found.
Our findings indicate that circulating AM is increased in type 2 diabetic patients and that increase correlates with poor glucose metabolic control and presence of retinopathy.
- SourceAvailable from: Randa M Matter[Show abstract] [Hide abstract]
ABSTRACT: Adrenomedullin (AM) is known to be elevated in different clinical situations including diabetes mellitus (DM), but its potential role in the pathogenesis of vascular complications in diabetic children and adolescents is to be clarified. Hence, the study aimed at assessment of plasma adrenomedullin levels in children and adolescents with type 1 DM and correlation of these levels with metabolic control and diabetic microvascular complications (MVC). The study was performed in the Diabetes Specialized Clinic, Children's Hospital of Ain Shams University in Cairo, Egypt. It included 55 diabetic children and adolescents (mean age 13.93 +/- 3.15 years) who were subdivided into 40 with no MVC and 15 with MVC. Thirty healthy subjects, age-and sex-matched, were included as control group (mean age 12.83 +/- 2.82 years). Patients and controls were assessed for glycosylated hemoglobin (HbA1c) and plasma adrenomedullin assay using ELISA technique. Mean plasma AM levels were significantly increased in patients with and without MVC compared to control group, (110.6 pg/mL, 60.25 pg/mL and 39.2 pg/mL respectively) (P < 0.01) with higher levels in those with MVC (P < 0.05). Plasma AM levels were positively correlated with both duration of diabetes (rho = 0.703, P < 0.001) and glycemic control (HbA1c) (rho = 0.453, P < 0.001). Higher plasma AM levels in diabetics particularly in those with MVC & its correlation with diabetes duration and metabolic control may reflect the role of AM in diabetic vasculopathy in the pediatric age group.Diabetology and Metabolic Syndrome 02/2010; 2:12. · 1.92 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: One of the major complications in patients with diabetes is diabetic retinopathy (DR), a leading cause of blindness worldwide. It takes several years before any clinical signs of retinopathy appear in diabetic patients, which gives an ample opportunity for scientists to uncover biochemical and molecular mechanism implicated early in the development and progression of the disease. During the past few decades, research progress has been made in investigating the pathophysiology of the disease; however, due to nonavailability of human retinal samples at different stages of the disease and also due to lack of a proper animal model of DR, the exact molecular mechanism has not been elucidated, making therapeutic a difficult task. In this review article, we have discussed a number of diabetes-induced metabolites such as glucose, lipids, amino acids, and other related factors and molecules that are implicated in the pathophysiology of the DR. Furthermore, we have highlighted neurodegeneration and regulation of neurotrophic factors, being recognized as early events that may be involved in the pathology of the disease in the course of DR. An understanding of the biochemical and molecular changes especially early in the diabetic retina may lead to new and effective therapies towards prevention and amelioration of DR, which is important for the millions of individuals who already have or are likely to develop the disease before a cure becomes available.Journal of diabetes and its complications 01/2012; 26(1):56-64. · 2.11 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The nitric oxide (NO) signaling pathway is integrally involved in visual processing and changes in the NO pathway are measurable in eyes of diabetic patients. The small peptide adrenomedullin (ADM) can activate a signaling pathway to increase the enzyme activity of neuronal nitric oxide synthase (nNOS). ADM levels are elevated in eyes of diabetic patients and therefore, ADM may play a role in the pathology of diabetic retinopathy. The goal of this research was to test the effects of inhibiting the ADM/NO signaling pathway in early diabetic retinopathy. Inhibition of this pathway decreased NO production in high-glucose retinal cultures. Treating diabetic mice with the PKC β inhibitor ruboxistaurin for 5 weeks lowered ADM mRNA levels and ADM-like immunoreactivity and preserved retinal function as assessed by electroretinography. The results of this study indicate that inhibiting the ADM/NO signaling pathway prevents neuronal pathology and functional losses in early diabetic retinopathy.Journal of ocular biology, diseases, and informatics 06/2011; 4(1-2):70-82.
Adrenomedullin plasma concentrations in patients
with retinitis pigmentosa
E.M. Vingoloa, S. Lupoa, D. Domanicoa, D. Cotestab, L. Petramalab, R. Grengaa, C. Letiziab,*
aDepartment of Ophthalmology, University of Rome ‘‘La Sapienza’’, Rome, Italy
bDepartment of Clinical Sciences, University of Rome ‘‘La Sapienza’’, Policlinico Umberto I, 00161 Rome, Italy
Received 18 November 2004; received in revised form 9 April 2005; accepted 15 April 2005
Available online 3 June 2005
Purpose: To evaluate the relationship between retinitis pigmentosa (RP) and plasma adrenomedullin (ADM) levels.
Methods: Blood samples were obtained from a group of 40 consecutive patients with RP matched with 35 healthy subjects (HS) as
control. We carried out a complete ophtalmological examination. The study group included 26 patients with RP and 14 patients with
syndromic RP. Plasma ADM levels were determined in duplicate with a specific radioimmunoassay method.
Results: In the HS plasma ADM levels were 13.7 T 6.1 pg/mL. The mean of plasma ADM concentrations in all patients with RP (23.4 T
10.7 pg/mL) was significantly (P < 0.0001) higher than that of HS. Moreover, in the syndromic RP patients, plasma ADM levels (28.6 T
14.35 pg/mL) were higher than those of HS and RP patients (P < 0.0017).
Conclusion: The increase of plasma ADM levels in RP patients may be a response to photoreceptor damage.
D 2005 The Canadian Society of Clinical Chemists. All rights reserved.
Keywords: Adrenomedullin; Retinitis pigmentosa; Syndromic retinitis pigmentosa
Adrenomedullin (ADM) is a novel peptide first isolated
from human pheochromocytoma . ADM has been
detected in plasma [2,3] and other biological fluids [3,4]
from healthy humans and may behave as a circulating
hormone. In plasma, ADM is specifically bound to
adrenomedullin-binding-protein-1 (AMBP-1), identified as
complement factor H . Cytokines, such as tumor necrosis
factor-a, and interleukin-1, lipopolysaccarides, circulating
hormones, such as corticosteroids, thyroid hormones,
angiotensin II, norepinephrine, endothelin-1 and bradykinin,
and physical stress and stretch may stimulate ADM
synthesis and secretion . Studies have revealed that
ADM is widely distributed in various organs and tissues
including the cardiovascular system (myocardium, vascular
endothelium, vascular smooth muscle), lung, kidney, and
endocrine system . ADM is expressed in the outer layer
of the retina, in particular in retinal pigment cells. ADM
dilates retinal arteries, decreases intraocular pressure, and
relaxes the sphincter smooth muscle cells. ADM concen-
tration in vitreous fluid is markedly increased in patients
with proliferative vitreoretinopathy, the most common
complication of retinal detachment originating from pro-
liferation of retinal pigment cells .
Retinal pigment epithelial (RPE) cells are located
between the neural retina and choroids of the eye and form
one component of the blood retinal barrier. RPE cells play
an essential role in the function and survival of photo-
receptors, including phagocytosis of the shed outer seg-
ments of rods and cones and synthesis and transportation of
many substances, such as vitamin A metabolites .
Retinitis pigmentosa (RP) is a primary, chronic, and here-
ditary chorioretinal degeneration characterized by photop-
sia, progressive visual loss with scotoma, and impairment of
dark adaptation . Although molecular biology and
0009-9120/$ - see front matter D 2005 The Canadian Society of Clinical Chemists. All rights reserved.
* Corresponding author. Fax: +39 6 49970524.
E-mail address: email@example.com (C. Letizia).
Clinical Biochemistry 38 (2005) 735 – 738
molecular genetics have identified many causative genes,
the molecular pathophysiology of RP is not fully under-
stood, and no effective treatments have been found yet. The
aim of our study was to investigate the behavior of plasma
ADM concentration in patients with RP and determine the
correlation between ADM and the intensity of retinal
Material and methods
A total of 40 consecutive patients with a diagnosis of
RP (18 F, 22 M, BMI 24.5 T 1.9 kg/m2, mean age 40 T 13
years) with normal renal function and no other medical
problems were enrolled. Several examinations were carried
out on the patients, such as indirect ophthalmoscopic,
manual visual field, electroretinogram (ERG), and visual-
evoked potential (PEV). The diagnosis of RP and all its
variants were made through a careful and experienced
interpretation of all the instrumental examinations. In our
study group, we found 26 patients with RP and 14 patients
with syndromic RP (8 patients affected by Usher’s
syndrome (US), 5 patients with a Cone Rod dystrophy,
and 1 with Laurence–Moon–Bardet–Biedl Syndrome
mean age 40 T 8 years) matched for age, gender, and BMI
were used as the control group. This study was approved by
a local ethic committee, and all subjects were kept in the
supine position for at least 60 min. 10 mL of venous blood
samples was collected from the antecubital vein between 8
and 9 a.m. after overnight fasting. 5 mL of blood was
collected in polystyrene tubes containing EDTA (1 mg/mL)
and aprotinin (500 KIU/mL). Blood samples were then
centrifuged at 3000 ?g at 0-C for 15 min. The plasma was
immediately stored in glass tubes at ?70-C until assayed.
Adrenomedullin (ADM) measurement
Plasma ADM concentration was measured after extrac-
tion and purification of samples in all subjects collected in
the morning after a supine rest of 30 min and stored at
?80-C until analyzed. Briefly, 2 mL of samples was applied
to conditioned Sep-pak C18 centridges (Millipore Corp.,
Waters Chromotography, Milford, MA, USA), and the
column was sequentially washed with 5 mL of isotonic
saline, 5 mL of 0.1% trifluoracetic acid, and 5 mL of 30%
acetonitrile in 0.1% trifluoracetic acid. The adsorbed
material was eluted with 4 mL of 50% acetonitrile, and
the eluted material was lyophilized. After lyophilization,
samples were dissolved in 50 mM phosphate buffer (pH 7.4),
and ADM was measured in plasma by RIA using a
commercial kit (Phoenix Pharmaceuticals Inc., Mountain
View, CA,USA) with rabbit polyclonal antibody raised
against human 1–52, as reported [11,12]. Each measure-
ment was performed in duplicate, and the averages were
reported. The antibody crossreacts 100% with human ADM,
and no crossreactivity was reported with rat ADM, amylin,
CGRP, endothelin-1, and a-atrial natriuretic peptide. The
two intra- and inter-assay coefficients of variance were 5.1%
and 12%, respectively. Recovery of synthetic human ADM
1–52 was 84.5%. The sensitivity of the assay was 2 pg/mL.
All results are expressed as mean T standard deviation
(SD). The statistical calculation was performed using
‘‘Primer’’ Software (Primer of Biostatistics, S.A. Glanz,
Fig. 1. (a) The scattered adrenomedullin (ADM) plasma values in patients with retinitis pigmentosa (RP), syndromic retinitis pigmentosa (syndromic RP), and
healthy subjects (HS). (b) Mean (TSD) plasma adrenomedullin (ADM) levels in patients with RP, syndromic RP, and HS.
E.M. Vingolo et al. / Clinical Biochemistry 38 (2005) 735–738
McGraw-Hill, San Francisco, USA). The individual values
were inserted by group on the spreadsheet and were inserted
by a non-parametric ANOVA test and Bonferroni’s t test,
where appropriate. The study of correlation was performed
by the Spearman test. A P value < 0.05 was considered
In the HS plasma, ADM levels ranged from 3.1–19.9
pg/mL, averaging 13.7 T 6.1 pg/mL. Mean plasma ADM
levels in all patients with RP (23.4 T 10.7 pg/mL) were
significantly higher (P < 0.0001) than those of HS (Fig.
1b). Fig. 1a shows the scattered values of plasma ADM
concentrations in all studied groups. ADM levels were
increased in all the RP subgroups: US patients (28.7 T
10.9 pg/mL) and Cone Rod patients (29.1 T 21.2 pg/mL).
The patient with LMBB showed high plasma ADM (26.1
pg/mL). Considering the whole sample for the syndromic
RP, the mean plasma level of ADM was 28.7 T 14.3 pg/
mL, and this value was significantly higher than those of
HS (13.7 T 6.1 pg/mL) and RP patients (23.4 T 10.7 pg/
mL) (P < 0.0017, respectively) (Fig. 1b). The study
correlation between pigmentary grading and ADM plasma
levels did not find a statistically significant correlation (r =
?0.09; P = 0.6). Table 1 shows the medians and
percentiles of ADM of our tapetoretinal degeneration
The current study was designed to assess the behavior of
plasma ADM levels in patients with RP. Our data revealed
an increase of plasma ADM concentrations in patients with
RP compared to HS, in particular in patients with syndromic
RP. These findings suggest that ADM may play a role in the
pathophysiology of the diseases that involve the retinal
pigment epithelial (RPE) cells such as RP.
Whereas ADM was first isolated from pheochromocy-
toma tissue and the concentration of the peptide is high in
the adrenal medulla , current evidence points to vascular
tissue, particularly endothelial cells , as likely being the
major source of circulating ADM in plasma . Moreover,
ADM is expressed in the outer layer of the retina, in
particular in retinal pigment cells .
Udono et al.  have demonstrated that human RPE
cells produce and secrete ADM and revealed that ADM
secreted from RPE cells, after treatment with cytokines
(IFN-g and IL-1h), plays an important role in some
inflammatory or degenerative diseases of the eyes. More-
over, these researchers demonstrated that hypoxia induced
the expression of ADM in human RPE cells  and
exogenously added ADM abolished the decrease in the
number of the hypoxia-induced RPE cells . These
findings suggest that ADM may have a protective effect
against hypoxic damage of the RPE cells.
Our data do not show a relation between pigmentary
grading and ADM plasma levels; in our view, this is
probably because pigmentation is not a parametric
variable so that we need more samples to achieve
significance. Moreover, pigmentation grading may also
depend on other patient characteristics such as iris color,
skin pigmentation, and refraction and consequently might
have variation that is not dependent upon ADM plasma
The increase of plasma ADM levels revealed in our RP
patients may be a response to photoreceptor damage, such
as scarring within the retina or may be due to a protective
effect on photoreceptor cells damaged by an altered photo-
transduction process. Moreover, the ADM production in
response to hypoxic stress may mimic the metabolic damage
secondary to the phototransduction alteration [10,17,18]. In
fact, some authors [15,16,18] demonstrated that the supple-
mentation of oxygen or vitamin A in patients with RP may
slow the degenerative process. The amount of ADM
produced by the eye, in particular by the RPE cells, might
seem to be small compared to the plasma compartment.
According to data presented by Udono et al. , this might
be explained by a secretion proportional to metabolic
damage that retinal tissue receives and in the case of
retinitis pigmentosa, retinal damage reaches 85–90% of the
We thank Mr. Giovanni Clemente for his technical
 Kitamura K, Matsui E, Kato J, et al. Adrenomedullin a novel
endogenous hypertensive peptide isolated from bovine adrenal
medulla. Biochem Biophys Res Commun 1993;192:553–60.
 Ichiki Y, Kitamura K, Kangawa K, et al. Distribution and character-
ization of immunoreactive adrenomedullin in porcine tissue, and
isolation of adrenomedullin [26–52] and adrenomedullin [34–52]
from porcine duodenum. J Biochem (Tokyo) 1995;118(4):765–70.
 Sato K, Hirata Y, Imai T, et al. Characterization of immunoreactive
adrenomedullin in human plasma and urine. Life Sci 1995;57(2):
Medians and percentiles of adrenomedullin from tapetoretinal degeneration
<10th 10th% 25th% 50th% 75th% 90th% >90th% Median
Syndro: syndromic retinitis pigmentosa; Rp: retinitis pigmentosa.
E.M. Vingolo et al. / Clinical Biochemistry 38 (2005) 735–738
 Di Iorio R, Marinoni E, Scavo D, et al. Adrenomedullin in pregnancy.
 Pio R, Martinez A, Unsworth EJ, et al. Complement factor H is a
serum-binding protein for adrenomedullin, and the resulting complex
2001;276(15):12292–300 [Electronic publication 2000 Dec 14].
 Sugo S, Minamino N, Shoji H, et al. Effects of vasoactive substances
and cAMP related compounds on adrenomedullin production in
cultured vascular smooth muscle cells. FEBS Lett 1995 (Aug 7);
369(2–3):311–4 [Erratum in: FEBS Lett 1996;379(2):201].
 Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional
regulatory peptide. Endocr Rev 2000;21(2):138–67.
 Udono-Fujimori R, Udono T, Totsune K, et al. Adrenomedullin in the
eye. Regul Pept 2003;112(1–3):95–101.
 Lamb TD, Pugh Jr EN. Dark adaptation and the retinoid cycle of
vision. Prog Retin Eye Res 2004;23(3):307–80.
 Sharma RK, Ehinger B. Management of hereditary retinal degener-
ations: present status and future directions. Surv Ophthalmol
 Letizia C, Cerci S, Centanni M. Circulating levels of adrenomedullin
levels in patients with Addison’s disease before and after cortico-
steroid treatment. Clin Endocrinol 1998;48:145–8.
 Di Iorio R, Marinoni E, et al. Adrenomedullin increases in term
asphyxiated newborns developing intraventricular hemorrhage. Clin
 Udono T, Takahashi K, Nakayama M, et al. Adrenomedullin in
cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis
 Udono T, Takahashi K, Nakayama M, et al. Induction of adrenome-
dullin by hypoxia in cultured retinal pigment epithelial cells. Invest
Ophthalmol Vis Sci 2001;42(5):1080–6.
 Berson EL. Nutrition and retinal degenerations. Int Ophthalmol Clin
 Li T, Sandberg MA, Berson EL, et al. Effect of vitamin A
supplementation on rhodopsin mutants threonine-17 Y methionine
and proline-347 Y serine in transgenic mice and in cell cultures. Proc
Natl Acad Sci U S A 1998;95(20):11933–8.
 Kemp CM, Jacobson SG, Stone EM, et al. RDS gene mutations
causing retinitis pigmentosa or macular degeneration lead to the same
abnormality in photoreceptor function. Invest Ophthalmol Vis Sci
 Vingolo EM, Pelaia P, Forte R, et al. Does hyperbaric oxygen (HBO)
delivery rescue retinal photoreceptors in retinitis pigmentosa? Doc
E.M. Vingolo et al. / Clinical Biochemistry 38 (2005) 735–738